C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study
about
Statins for the primary prevention of cardiovascular diseaseIdentifying novel biomarkers for cardiovascular disease risk predictionOvercoming Challenges With Statin TherapyIncorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial)Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic strokeHomocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at RiskTime variability of C-reactive protein: implications for clinical risk stratification.Statin therapy after infrainguinal bypass surgery for critical limb ischemia is associated with improved 5-year survivalC-reactive protein levels in patients at cardiovascular risk: EURIKA studyCoexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease.Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study.Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes TrialThe role and clinical significance of high-sensitivity C-reactive protein in cardiovascular disease.Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials.Reducing serum cholesterol levels in women.Influence of atherosclerosis-related risk factors on serum high-sensitivity C-reactive protein levels in patients with type 2 diabetes: Comparison of their influence in obese and non-obese patients.A Novel Medical Treatment for Lipid Control in Patients with Unstable Angina Pectoris and Statin-Induced Liver Dysfunction.Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.C-reactive protein, fibrinogen, and cardiovascular disease prediction.Hypertension in pregnancy is associated with elevated C-reactive protein levels later in life.Statins, inflammation and kidney disease.C-reactive protein, statins and the risk of vascular events: a better understanding.Inflammatory markers in coronary heart disease.Role of C-reactive protein when prescribing a statin.Dyslipidemia: management using optimal lipid-lowering therapy.Between risk charts and imaging: how should we stratify cardiovascular risk in clinical practice?How low an LDL-C should we go with statin therapy?High-Sensitivity C-Reactive Protein and Statin Initiation.The JUPITER trial: myth or reality?Clinical relevance for lowering C-reactive protein with statins.Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.The effect of periodontal treatment on C-reactive protein: A clinical study.Effects of pitavastatin on walking capacity and CD34+/133+ cell number in patients with peripheral artery disease.Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial.Treatment of patients with intermediate cardiovascular risk: Are clinical measures enough?Effects of low-fat or full-fat fermented and non-fermented dairy foods on selected cardiovascular biomarkers in overweight adults.Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia.Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
P2860
Q24201513-4E4BADFB-1756-4F77-A57A-C4891374BC22Q26865722-3DC6BA54-8568-40FC-95D3-AED706B0C26CQ28073319-32F69039-75C3-492D-8442-8547E6937C43Q30731532-221C7709-DC72-4EA9-94FB-375A95249683Q33922922-E52F96F7-4DE3-4165-B92C-8D3B543D6C3DQ34095488-BA293AA5-67F0-4284-8B2F-87A6222413EFQ34516430-84CBA120-4EA3-4851-93A6-B61D97E13E7CQ34665888-C015855C-7508-41F9-9DAE-A7CFD579C960Q34812017-2E840D81-6F49-4BB1-9D11-82A717BE8662Q35101153-87FC47E2-EDD9-4B33-BC7D-4A1A3EC6D28AQ35153209-97FF05D8-1549-45EE-8BFE-ED9DFF6642E0Q35213010-C5AC3F23-9781-46CD-BF56-1B973992BFC9Q35756468-80731A8B-CE67-4439-ADD6-A99829CA80BAQ35757048-116874A0-09E6-49FA-A5DA-20DA6F36291AQ35866695-7A8D82F8-6CF2-44E7-843C-403C82C04456Q36088110-A5292D7E-801C-4DE8-BC7A-5AE59C45CBCAQ36247131-D39F4CB1-2143-41AE-9119-D311109D568AQ36637949-5366BC68-7B92-44D2-90AD-5B4ABB816135Q36721590-03FDFD9F-854B-44AC-91EC-87E0F6B19C05Q37000223-A2E77B62-DCCE-4E1B-9EA3-8C223B1127F1Q37021409-D75CDE74-37DB-45CC-813A-0D4CD28FDC3EQ37586959-BB9A8EFA-63E9-4763-93CE-A774402B3F46Q37883015-6DAFF4D2-5D81-4C1C-A477-EF728946A5ACQ37906353-CA49F61E-CA93-44A1-8943-849D8AB5CC45Q37947242-7F80113B-4E72-44D2-8AEC-9CC59F46D650Q37962460-312C1D76-1885-4BE7-8A10-519DA990ACDBQ38049066-8E3AEB4F-A8F9-441C-8B03-CA833F71DBA1Q38072595-CD290268-FC01-47F7-B2CD-69AB87326BC4Q38176273-C539A8C2-2D85-4AEF-8021-E7183C24BA0FQ38233001-35F39274-CBA8-4A81-9132-A9EBAE0D5282Q38462688-3601B4DB-B890-4D8A-9CC6-C13FFC9A4301Q38880500-849848E2-DBEB-48EB-9CFF-A91BE5E0E9CDQ39215606-CF265556-06D6-4774-B8DA-73A4FB66C1D1Q41967368-5E80ED8F-DFB9-418C-B7E8-8378CADD296DQ42021710-C869204B-791F-441D-B3E3-2A1B3B7FE866Q44973053-42E0265D-8DB2-482E-AA22-2311DE97CC1BQ45125528-CCE34952-364A-4525-9965-2571FE6B2FC9Q45191361-CD7443E7-1CA1-45E8-B6E5-23F5626F19E3Q45822783-9776635D-C939-4B03-B92A-9CD6A43269FAQ47394637-D2B394EF-04BB-4E64-8B9C-0AFE91CFB325
P2860
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
C-reactive protein concentrati ...... in the Heart Protection Study
@ast
C-reactive protein concentrati ...... in the Heart Protection Study
@en
C-reactive protein concentrati ...... in the Heart Protection Study
@nl
type
label
C-reactive protein concentrati ...... in the Heart Protection Study
@ast
C-reactive protein concentrati ...... in the Heart Protection Study
@en
C-reactive protein concentrati ...... in the Heart Protection Study
@nl
prefLabel
C-reactive protein concentrati ...... in the Heart Protection Study
@ast
C-reactive protein concentrati ...... in the Heart Protection Study
@en
C-reactive protein concentrati ...... in the Heart Protection Study
@nl
P2093
P2860
P1433
P1476
C-reactive protein concentrati ...... in the Heart Protection Study
@en
P2093
Derrick Bennett
Jane Armitage
John Danesh
Jonathan Emberson
P2860
P304
P356
10.1016/S0140-6736(10)62174-5
P407
P577
2011-02-05T00:00:00Z